Mumbai, July 27 -- Revenue from operations increased 37% year-on-year (YoY) to Rs 449.02 crore in Q1 FY27 from Rs 3,273 crore in Q1 FY26, driven by the commercial launch of semaglutide, new master service agreement (MSA) contracts, and customer wins across its business segments.

The company reported a profit before exceptional items and tax of Rs 24.59 crore during the quarter, compared with a loss before exceptional items and tax of Rs 1.52 crore in the year-ago period.

During the quarter, the company recorded an exceptional loss of Rs 4.30 crore on account of legal charges related to legacy litigation involving employees of a subsidiary.

EBITDA stood at Rs 123.3 crore, registering the growth of 39% YoY. EBITDA margin improved to 27.5...